Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Active not recruiting 3Suspended 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1

Interventions

Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Antibodies, Monoclonal 2sargramostim 1prednylidene 1pembrolizumab 1glucarpidase 1deltacortene 1brincidofovir 1Specimen Handling 1Rituximab 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Methods 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunotherapy, Active 1Immunization, Passive 1Health Care Economics and Organizations 1Etoposide 1Drug Therapy 1Coal Tar 1Brentuximab Vedotin 1Biopsy 1Biomarkers 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma × Methods × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡